Cullinan Therapeutics, Inc. CGEM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$221.04M-0.5% | -$219.88M-1.4% | -$216.81M-4.9% | -$206.76M-15.7% | -$178.74M-6.7% | ||
| $314K+1.0% | $311K+0.6% | $309K+1.0% | $306K0.0% | $306K0.0% | ||
| $34.28M-4.9% | $36.04M-6.1% | $38.36M+0.1% | $38.33M-1.7% | $38.97M+3.0% | ||
| -$178.64M-1.6% | -$175.75M-0.9% | -$174.27M-1.6% | -$171.53M-14.2% | -$150.21M-3.4% | ||
| —— | —— | —— | —— | —— | ||
| $175.6M-2.4% | $179.99M— | —— | —— | —— | ||
| $1.47M+34.9% | $1.09M-44.3% | $1.96M-40.4% | $3.28M-98.8% | $265.1M-0.4% | ||
| —— | —— | $1.25M+103% | -$42.2M-1,839% | $2.43M+116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cullinan Therapeutics, Inc. generate?
- Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.
- Where does Cullinan Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.